抗体靶向的免疫激动性药物在肿瘤免疫治疗中的研究进展  

Research Progress of Antibody-targeted Immunoagonistic Drugs in Tumor Immunotherapy

作　　者：汪雅琳 陈小青 许涛 刘雪 罗文新[1] WANG Yalin;CHEN Xiaoqing;XU Tao;LIU Xue;LUO Wenxin(National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Public Health,XiamenUniversity,Xiamen 361102,China)

机构地区：[1]厦门大学公共卫生学院,国家传染病诊断试剂与疫苗工程技术研究中心,厦门361102

出　　处：《中国生物工程杂志》2024年第6期78-89,共12页China Biotechnology

基　　金：国家自然科学基金(32070940);博士后创新人才支持计划(BX20220189)资助项目。

摘　　要：免疫细胞功能受共抑制受体和共刺激受体的调控。免疫检查点抑制剂在肿瘤治疗中被广泛应用,但其疗效受到免疫抑制性肿瘤微环境的影响。靶向共刺激受体的激动性抗体或其对应的配体等免疫激动性药物能增强免疫系统的抗肿瘤反应,成为新一代肿瘤治疗策略。介绍近年不同类型免疫激动性药物,并综述基于抗体靶向的免疫激动性药物在肿瘤免疫治疗领域中的研究进展,以期为下一代免疫激动性药物的研发提供新思路。Immune cell function is regulated by co-inhibitory and costimulatory receptors.Although immune checkpoint inhibitors are widely utilized in tumor therapy,their efficacy is hampered by the immunosuppressive tumor microenvironment.Immunoagonistic drugs,such as agonistic antibodies or their corresponding ligands targeting costimulatory receptors,have the potential to enhance the immune system's anti-tumor response and are emerging as a new generation of cancer treatment strategies.This review aims to introduce various types of immunoagonistic drugs developed in recent years and to evaluate the research progress of antibody-targeted immunoagonistic drugs in the field of tumor immunotherapy,in order to provide new insights for the development of the next generation of immunoagonistic drugs.

关 键 词：抗体 免疫激动性药物 免疫治疗 肿瘤 

分 类 号：Q819[生物学—生物工程]